Acceder Registro /

ALBERTO BAROJA MAZO

Buscador

Re OL, Lopez-Lopez V, Balaguer-Roman A, Martinez-Sanchez MA, Eshmuminov D, Llamoza-Torres CJ, Miura K, Baroja-Mazo A, Ramirez P, Robles-Campos R, Ramos-Molina B. New challenges in cholangiocarcinoma candidates for elective surgery: harnessing the microbiome dysbiosis. Langenbecks Arch Surg. 2023 Mar 31;408(1):134. doi: 10.1007/s00423-023-02867-8. PubMed PMID: 37000331.
AÑO: 2023; IF: 2.3
Villalba-Lopez F, Saenz-Mateos LF, Sanchez-Lorencio MI, De La Orden-Garcia V, Alconchel-Gago F, Cascales-Campos PA, Garcia-Bernardo C, Noguera-Velasco JA, Baroja-Mazo A, Ramirez-Romero P. Usefulness of PIVKA-II for monitoring after liver transplantation in patients with hepatocellular carcinoma. Sci Rep. 2023 Apr 6;13(1):5621. doi: 10.1038/s41598-023-32879-9. PubMed PMID: 37024609; PubMed Central PMCID: PMC10079651.
AÑO: 2023; IF: 4.6
Villalba-Lopez F, Garcia-Bernal D, Mateo SV, Vidal-Correoso D, Jover-Aguilar M, Alconchel F, Martinez-Alarcon L, Lopez-Lopez V, Rios-Zambudio A, Cascales P, Pons JA, Ramirez P, Pelegrin P, Baroja-Mazo A. Endothelial cell activation mediated by cold ischemia-released mitochondria is partially inhibited by defibrotide and impacts on early allograft function following liver transplantation. Biomed Pharmacother. 2023 Sep 18;167:115529. doi: 10.1016/j.biopha.2023.115529. Online ahead of print. PubMed PMID: 37729732.
AÑO: 2023; IF: 7.5
Martinez-Banaclocha H, Garcia-Palenciano C, Martinez-Alarcon L, Amores-Iniesta J, Martin-Sanchez F, Ercole GA, Gonzalez-Lisorge A, Fernandez-Pacheco J, Martinez-Gil P, Padilla-Rodriguez J, Baroja-Mazo A, Pelegrin P, Martinez-Garcia JJ. Purinergic P2X7 receptor expression increases in leukocytes from intra-abdominal septic patients. Front Immunol. 2023 Nov 29;14:1297249. doi: 10.3389/fimmu.2023.1297249. eCollection 2023. PubMed PMID: 38094297; PubMed Central PMCID: PMC10716420.
AÑO: 2023; IF: 7.3
Baroja-Mazo A, Penin-Franch A, Lucas-Ruiz F, de Torre-Minguela C, Alarcon-Vila C, Hernandez-Caselles T, Pelegrin P. P2X7 receptor activation impairs antitumour activity of natural killer cells. Br J Pharmacol. 2023 Jan;180(1):111-128. doi: 10.1111/bph.15951. Epub 2022 Oct 3. PubMed PMID: 36098250.
AÑO: 2023; IF: 7.3

Instituto de Investigación Sanitaria Acreditado

ISCII

Fondo Social Europeo "El FSE Invierte en tu futuro"

Fondo Social Europeo

Sello de Calidad Europeo "HR Excellence in Research"

HRS4R